117 related articles for article (PubMed ID: 9651157)
1. Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist.
Tecle H; Barrett SD; Lauffer DJ; Augelli-Szafran C; Brann MR; Callahan MJ; Caprathe BW; Davis RE; Doyle PD; Eubanks D; Lipiniski W; Mirzadegan T; Moos WH; Moreland DW; Nelson CB; Pavia MR; Raby C; Schwarz RD; Spencer CJ; Thomas AJ; Jaen JC
J Med Chem; 1998 Jul; 41(14):2524-36. PubMed ID: 9651157
[TBL] [Abstract][Full Text] [Related]
2. CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology.
Tecle H; Schwarz RD; Barrett SD; Callahan MJ; Caprathe BW; Davis RE; Doyle P; Emmerling M; Lauffer DJ; Mirzadegan T; Moreland DW; Lipiniski W; Nelson C; Raby C; Spencer C; Spiegel K; Thomas AJ; Jaen JC
Pharm Acta Helv; 2000 Mar; 74(2-3):141-8. PubMed ID: 10812951
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists.
Tecle H; Lauffer DJ; Mirzadegan T; Moos WH; Moreland DW; Pavia MR; Schwarz RD; Davis RE
Life Sci; 1993; 52(5-6):505-11. PubMed ID: 8382765
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.
Jaen J; Barrett S; Brann M; Callahan M; Davis R; Doyle P; Eubanks D; Lauffer D; Lauffer L; Lipinski W
Life Sci; 1995; 56(11-12):845-52. PubMed ID: 10188784
[TBL] [Abstract][Full Text] [Related]
5. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
Bromidge SM; Brown F; Cassidy F; Clark MS; Dabbs S; Hadley MS; Hawkins J; Loudon JM; Naylor CB; Orlek BS; Riley GJ
J Med Chem; 1997 Dec; 40(26):4265-80. PubMed ID: 9435896
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and muscarinic M3 pharmacological activities of 1-azabicyclo[2.2.2]octan-3-one oxime derivatives.
Plate R; Plaum MJ; de Boer T; Andrews JS
Bioorg Med Chem; 1996 Feb; 4(2):239-45. PubMed ID: 8814881
[TBL] [Abstract][Full Text] [Related]
7. 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
Pei XF; Gupta TH; Badio B; Padgett WL; Daly JW
J Med Chem; 1998 Jun; 41(12):2047-55. PubMed ID: 9622546
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors.
Böhme TM; Augelli-Szafran CE; Hallak H; Pugsley T; Serpa K; Schwarz RD
J Med Chem; 2002 Jul; 45(14):3094-102. PubMed ID: 12086495
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
Messer WS; Abuh YF; Liu Y; Periyasamy S; Ngur DO; Edgar MA; El-Assadi AA; Sbeih S; Dunbar PG; Roknich S; Rho T; Fang Z; Ojo B; Zhang H; Huzl JJ; Nagy PI
J Med Chem; 1997 Apr; 40(8):1230-46. PubMed ID: 9111297
[TBL] [Abstract][Full Text] [Related]
10. Deoxamuscaroneoxime derivatives as useful muscarinic agonists to explore the muscarinic subsite: demox, a modulator of orthosteric and allosteric sites at cardiac muscarinic M2 receptors.
Angeli P; Marucci G; Buccioni M; Piergentili A; Giannella M; Quaglia W; Pigini M; Cantalamessa F; Nasuti C; Novi F; Maggio R; Qasem AR; Spampinato S
Life Sci; 2002 Feb; 70(12):1427-46. PubMed ID: 11883718
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and muscarinic activities of O-[(benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone.
Rodríguez-Franco MI; Dorronsoro I; Castro A; Martínez A; Badía A; Baños JE
Bioorg Med Chem; 2003 May; 11(10):2263-8. PubMed ID: 12713836
[TBL] [Abstract][Full Text] [Related]
12. 1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives.
Jeppesen L; Olesen PH; Hansen L; Sheardown MJ; Thomsen C; Rasmussen T; Jensen AF; Christensen MS; Rimvall K; Ward JS; Whitesitt C; Calligaro DO; Bymaster FP; Delapp NW; Felder CC; Shannon HE; Sauerberg P
J Med Chem; 1999 Jun; 42(11):1999-2006. PubMed ID: 10354408
[TBL] [Abstract][Full Text] [Related]
13. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and muscarinic activity of 1,2,3,4-tetrahydropyrimidine derivatives.
Jung MH; Park JG; Yang KJ; Lee MJ
Arch Pharm (Weinheim); 2001 Mar; 334(3):79-85. PubMed ID: 11315338
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone.
Wu ES; Kover A; Semus SF
J Med Chem; 1998 Oct; 41(22):4181-5. PubMed ID: 9784090
[No Abstract] [Full Text] [Related]
16. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
[TBL] [Abstract][Full Text] [Related]
17. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
Sheardown MJ; Shannon HE; Swedberg MD; Suzdak PD; Bymaster FP; Olesen PH; Mitch CH; Ward JS; Sauerberg P
J Pharmacol Exp Ther; 1997 May; 281(2):868-75. PubMed ID: 9152396
[TBL] [Abstract][Full Text] [Related]
18. Activity and QSAR study of baogongteng A and its derivatives as muscarinic agonists.
Niu YY; Yang LM; Liu HZ; Cui YY; Zhu L; Feng JM; Yao JH; Chen HZ; Fan BT; Chen ZN; Lu Y
Bioorg Med Chem Lett; 2005 Nov; 15(21):4814-8. PubMed ID: 16153841
[TBL] [Abstract][Full Text] [Related]
19. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
Langmead CJ; Austin NE; Branch CL; Brown JT; Buchanan KA; Davies CH; Forbes IT; Fry VA; Hagan JJ; Herdon HJ; Jones GA; Jeggo R; Kew JN; Mazzali A; Melarange R; Patel N; Pardoe J; Randall AD; Roberts C; Roopun A; Starr KR; Teriakidis A; Wood MD; Whittington M; Wu Z; Watson J
Br J Pharmacol; 2008 Jul; 154(5):1104-15. PubMed ID: 18454168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
